ABSTRACT: Introduction: Polyneuropathy signs (Neuropathy Impairment Score, NIS), neurophysiologic tests (m17 Ionis ), disability, and health scores were assessed in baseline evaluations of 100 patients entered into an oligonucleotide familial amyloidotic polyneuropathy (FAP) trial.
Methods: We assessed: (1) Proficiency of grading neurologic signs and correlation with neurophysiologic tests, and (2) clinometric performance of modified NIS17 neurophysiologic tests (mNIS17 Ionis ) and its subscores and correlation with disability and health scores.
Results: The mNIS17 Ionis sensitively detected, characterized, and broadly scaled diverse polyneuropathy impairments. Polyneuropathy signs (NIS and subscores) correlated with neurophysiology tests, disability, and health scores. Smart Somatotopic Quantitative Sensation Testing of heat as pain 5 provided a needed measure of small fiber involvement not adequately assessed by other tests.
Conclusions: Specially trained neurologists accurately assessed neuropathy signs as compared to referenced neurophysiologic tests. The score, mNIS17 Ionis , broadly detected, characterized, and scaled polyneuropathy abnormality in FAP, which correlated with disability and health scores.
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Transthyretin amyloidosis (ATTR) is a fatal dominantly inherited disease due to >100 point mutations of transthyretin (TTR), a transport protein of thyroxine and retinol -binding protein mainly synthesized by the liver (Study data were collected and managed using REDCap electronic data capture tools hosted at Mayo Clinic, Center for Clinical and Translational Science grant support). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Typically, the disease manifests in early or later adult life as a symmetric length-dependent sensorimotor-autonomic polyneuropathy, also called familial amyloidotic polyneuropathy (FAP). 11, [13] [14] [15] [16] [17] [18] The polyneuropathy may be overshadowed by cardiomyopathy or other organ involvement. 12, 19 Recently, ATTR has received increasing attention, because it is fatal, may be more common than usually recognized 10, 15 and has become treatable. 14, 20 Although still not adequately evaluated, orthotopic liver transplantation, resulting in marked reduction of circulating mutant TTR, appears to slow disease progression. [21] [22] [23] Stabilization of circulating tetrameric protein TTR using Vyndaqel V R or Diflunisal slows FAP progression. 14, 20 Oligonucleotide therapies directed at TTR messenger RNA have been shown to markedly reduce both mutant and wild plasma TTR levels and are in phase 3 clinical trials. 24, 25 In a previous retrospective review of Mayo Clinic (Rochester, Minnesota) patients with FAP, we assessed the clinometric properties of NIS17 (a composite score of polyneuropathy signs and neurophysiologic tests) to quantitate the overall kind and severity of polyneuropathy impairment in FAP. 17 The score broadly characterized and quantified muscle weakness, muscle stretch reflex decrease, sensation loss of feet and hands, and neurophysiologic test abnormalities. From analysis of the data, 3 modifications of NIS17 were recommended to more broadly and adequately represent the diversity and severity of polyneuropathy impairments: (1) assess sensation loss of both large and small fiber modalities somatotopically using validated approaches and suitable reference values; (2) assess only amplitudes of attributes of nerve conduction (NC) and include attributes of an upper limb nerve, e.g., the ulnar nerve; and (3) assess sudomotor decrease at distributed body sites.
In a recently published multinational study, rapid progression of FAP was demonstrated using the Neuropathy Impairment Score (NIS), and its severity was correlated with functional scales of locomotion. 18 The ongoing Phase 3 FAP clinical trials with TTR lowering agents (IONIS-TTR Rx and patisiran) 24, 25 use modifications of NIS17 scores that have incorporated the first 2 of the 3 recommended modifications suggested above. The modified NIS17 scores differ slightly, and herein the score used in the IONIS-TTR Rx trial (NEURO-TTR) is referred to as mNIS17 Ionis .
This study assessed the clinometric performance of polyneuropathy signs (NIS) and neurophysiologic tests (m17 Ionis ) in evaluation at baseline of the first 100 FAP patients entered into the NEURO-TTR trial. The following questions were addressed: (1) do NIS and its subscores and m17 neurophysiologic tests adequately detect, characterize, and scale polyneuropathy abnormalities and their severity in FAP; (2) In addition, patients were excluded if they had a prior history of liver transplantation, diabetes mellitus, or the presence of other causes of polyneuropathy and were not allowed to receive TTR stabilizing drugs during the study.
Description of Polyneuropathy Endpoints. The NIS has been described extensively and used in previously published therapeutic trials in chronic inflammatory demyelinating polyradiculoneuropathy, 26, 27 polyneuropathy associated with monoclonal gammopathies of undetermined significance, 28 and diabetic sensorimotor polyneuropathies. 29, 30 The NIS comprises scores of muscle weakness (NIS-W, 0-192), decrease of muscle stretch reflexes (NIS-R, 0-20), and abnormality of 4 sensory modalities of sensation loss in the toes and fingers (NIS-S, 0-32); the total NIS score may vary from 0 to 244. The NIS components (clinical assessments) are the same in NIS17 as in modification of NIS17 (mNIS17 Ionis ).
The NIS17 and mNIS17 Ionis differ in the neurophysiologic tests in the 17. To provide a more accurate and representative assessment of the kind and distribution of sensation loss in the mNIS17 Ionis , the VDT of the great toe was replaced by Smart Somatotopic Quantitative Sensation Testing (S ST QSTing) of touch-pressure (TP) and heat as pain 5 (HP5) (of 1-10 severity) of the body surface area. 14, 17 As directed by the algorithm, up to 10 distributed unilateral anatomical sites are tested. Healthy subject reference values are available for all 10 assessed sites and for both TP and HP5 sensation (reference data unpublished). The automated algorithm of testing of S ST QSTing assumes that sensation loss in FAP is symmetric and length dependent. For a patient with only distal sensation loss of lower and upper limbs, only 4 distal sites of 1 side of the body require testing. For a patient with generalized sensation loss, a variable number of sites (up to 10) may need to be tested. The S ST QSTing score ranges from 0 to 80 depending on the severity and distribution of sensation loss. In addition, the mNIS17 Ionis uses different attributes of NC than were used in NIS17, including an upper limb nerve. The attributes in mNIS17 Ionis include CMAPs of ulnar, fibular, and tibial nerves and SNAPs of ulnar and sural nerves. This change was made to use measures of amplitude over measures of conduction velocity or distal latency. Attributes of NC are expressed as NDs from percentiles as described for mNIS17 Ionis . The HR db remains unchanged in mNIS17 Ionis from that used in NIS17. 32, 33 Approaches Used to Accurately Assess Clinical Signs and Neurophysiologic Tests. Because mNIS17 Ionis uses assessment of clinical neuropathy signs and neurophysiologic tests, emphasis was placed on choice of investigators, training, proficiency, and adequate handling of their clinical measurements. Neurologists chosen for the trial had to be faculty neurologists who planned to evaluate the same patient over the duration of the trial. 34 They were trained neurologists or clinical neurophysiologists, typically on the teaching staff of a Neurology department in a medical school. To obtain uniformity of grading, all received special training and certification by members of the Mayo Clinic Peripheral Neuropathy Research Laboratory (MC PNRL). Healthy subjects and patients with FAP were used in training. In assessment of neuropathy signs, specificity was emphasized over sensitivity based on results of recently published Cl versus NPhys trials results. [34] [35] [36] As much as was possible at each clinical trial site, separate personnel performed the different neuropathy assessments, i.e., neurologic examinations, NC studies, S ST QSTing, and autonomic testing. Study site personnel did not summate test scores; this was done later at the MC PNRL. Several additional strategies were used to make independent assessments. The duplicate neuropathic assessments had to be separated by at least 24 h. The tracings of attributes of NC were carefully reviewed in the MC PNRL by one of the authors (W.J.L.) to evaluate the adequacy of test performance. The conversion of NC measurements to percentiles and NDs was done later by programmed calculations in the MC PNRL. The performance of S ST QSTing and HR db was directed by Smart algorithms and reference values.
After special training and certification, and before onset of the trial, examiners submitted test results of all neuropathy evaluations of a healthy subject aged < 50 years and another 50 years. This was done to ensure adequate performance of the tests and approval of test performance by the MC PNRL personnel. In assessment of polyneuropathy signs, neurologists were asked to grade as abnormal only unequivocal abnormality related to FAP and taking age, gender, and anthropomorphic variables into account. 34, 35 Standard paper/electronic forms were used for entry of neuropathic signs, symptoms, and neurophysiologic tests. 1, 36 Examiners were asked to use a scribe to record neuropathy signs as they were elicited to avoid transcription error. 27 Signs and neurophysiologic test results were transmitted electronically to the MC PNRL.
Neurophysiologic tests were done by trained and certified clinical neurophysiologists or their technologists, both of whom had received specially prepared syllabi and special training. For assessment of S ST QSTing, automated and highly standardized equipment (prototypes developed at Mayo Clinic, Rochester, Minnesota and fabricated to industry standards at WR Medical Electronics, Maplewood, Minnesota) was made available to every clinical site. The S ST QSTing algorithms of testing and estimated thresholds were developed by one of the authors (P.J.D.) and programmed for use for QSTing by WR Medical Electronics. It uses highly standardized and automated stimuli, algorithms of testing, and finding threshold and reference values, and its accuracy and proficiency has been demonstrated. 33 
Neuropathic
Symptoms, Disability, and Health
Scores. Three health and disability scores were used to evaluate overall functional disability: the PND, Dyck/Rankin score, and the INCAT from the NSC score. The INCAT from NSC score assesses disability due to weakness of distal and proximal muscles of upper and lower limbs and scores abnormality from 1 to 10. Also assessed were 2 health scores, Norfolk QOL-DN and the SF-36.
Analysis Plan. At a conceptual level, abnormality of clinical signs, symptoms, and neurophysiologic tests were set at a fifth or first percentile level and as corrected for age, gender, and anthropomorphic variables. In this study, such reference values were available from a healthy subject cohort drawn from the Olmsted County, Minnesota, population with subjects excluded based on neurologic evaluation and review of their medical records. 31, 37 Individuals with diabetes, metabolic diseases, or polyneuropathy were excluded. Highly standardized approaches were used to evaluate attributes of NC, quantitative sensation, and autonomic tests. 31, 37 These neuropathic test results were assessed for the influence of age, gender, and anthropomorphic variables. Results were expressed as measured values, percentiles, and NDs.
Data were analyzed using standard statistical techniques with a primary intention to quantitate neuropathy signs and neurophysiologic test abnormalities and to describe associations between the various FAP measurements including NIS (points), R5 NCs (NDs), S ST QSTing (points), S ST QSTing of TP (points), S ST QSTing of HP5 (points), HR db (NDs), and dysfunction, disability, and health scores. Test/retest reproducibility results were assessed for a significant degree of agreement using the Krippendorff alpha.
The accuracy of individual clinical signs was assessed by Spearman correlations with a comparable neurophysiologic test, with the 2 evaluations determined independently. Eleven such comparisons were possible. In the 11 available comparisons, the neurophysiologic tests were judged to be the gold standard evaluation, because they were more objective, standard, quantitated, and referenced as compared with the neuropathic signs clinically evaluated. For a broader exploration of the correlations among assessed neuropathy signs (NIS) or their subscores (NIS-W, -R, or -S), they were compared with composite disability or health scores.
In several tables, Spearman rank correlation coefficients (r) and P-values (P) were combined into 6 strata to provide simplified expressions of strength and significance of correlations. Multiple comparisons were conducted, so a Bonferroni correction was applied to the P-values as needed in Table 1 . When adjusted P-values are reported, they are clearly noted. Statistical analysis was conducted using the SAS System version 9.3 (Cary, North Carolina).
RESULTS
Demographic and Baseline Characteristics. The patients were recruited from 16 medical centers Seventy-six were women, and 24 were men. Their median age was 65, range 27-81 years. Non-USA patients (n 5 35) had a higher frequency of Val30-met mutations (66%) than did USA patients (25%).
The test/retest reproducibility of signs (NIS), symptoms (NSC), attributes of NC (i.e., R5 NC, S ST QSTs of TP or HP5), and HR db are given in Table 1 . Note the high reproducibility values for neuropathic signs (NIS), NCs (R5 NCs), and HR db . The reproducibility value for S ST QSTing is 
Correlation of Composite Measure of Polyneuropathy
Signs (NIS) with Neurophysiological Tests (m17 Ionis ). As shown in Table 3 , strong correlations were observed between assessments of clinically assessed neuropathic signs (NIS) or symptoms (NSC) and neurophysiologic tests. The correlation of polyneuropathy signs (NIS) with m17 Ionis neurophysiologic tests performed as well or better than did any subscores of signs with neurophysiologic tests. Polyneuropathy signs (NIS) and symptoms (NSC) correlated more strongly with the modified attributes of NC using only motor and sensory amplitudes (the attributes used in mNIS17 Ionis ) than with those used in NIS17 attributes (used for study of diabetic polyneuropathy) (data not shown). Clinical measures of polyneuropathy signs or symptoms correlated strongly with somatotopic assessment of TP but not with somatotopic assessment of HP5; the latter is a measure of small sensory fiber dysfunction. Similarly, scored signs (NIS) and symptoms (NSC) did not correlate with HR db . By contrast, the autonomic sub-score of NSC correlated at a low level of significance with measured HP5 (S ST QSTing of HP5) and with HR db .
Correlation of Neuropathy Signs and Neurophysiologic
Tests with Disability and Health Scores. The data are shown in Table 4 . Considering the correlation between signs and neurophysiologic tests, the strongest correlations occurred between mNIS17 Ionis and disability and health scores. Almost as strong correlations were obtained for NIS total or from the weakness (NIS-W) subscore and disability and health scores. The correlation between reflexes (NIS-R) and disability and health scores was not as strong. The correlations between symptom scores (NSC) provided confirmatory information. Symptoms of weakness (NSC weakness) and sensory loss (NSC sensation) correlated strongly with disability and health scores. Scores of positive neuropathic sensory symptoms, pain, and autonomic scores correlated at lower levels of significance with disability and health scores. Somatotopic evaluation of TP but not of heat as pain sensation correlated with all disability and health scores.
In Figure 2 , we show the distribution of mNIS17 Ionis score values of FAP patients staged by the PND. Scored values are significantly different among the three stages.
DISCUSSION
Previously published cohort studies of FAP 2, 6, 7, 11, 15, 16, 18 found considerable variability in age of onset, clinical manifestations, and course of this polyneuropathy. To illustrate, the somatotopic distribution and severity of muscle weakness, muscle stretch reflex decrease, the balance of large to small fiber sensation loss, and autonomic deficits varied considerably among patients. This variability of clinical expression, the rarity of FAP, and the desire to include a representative cohort of FAP impairments were important considerations in the choice to use a composite neuropathy score as an outcome measure in the NEURO-TTR trial. mNIS17 Ionis was designed to somatotopically quantitate muscle weakness and large and small fiber sensory loss. Autonomic dysfunction, however, was not assessed somatotopically and, as shown here, HR db is not an adequate outcome measure of small fiber involvement in FAP.
Neurophysiologic test results (m17) were added to a score of clinical signs (NIS) for 2 reasons: (1) for m17 Ionis tests to serve as reference standards against which accuracy of assessment of clinical signs could be compared, and (2) to aid in comprehensive scoring of FAP impairments. We reasoned that use of such composite scoring would not prevent it from demonstrating a meaningful beneficial effect, assuming that an efficacious treatment would benefit all kinds and severities of FAP impairments.
In our analysis of the first 100 FAP patients from 6 different countries entered into the NEURO-TTR trial, we found that a broad range of polyneuropathy functional impairments and severities had been recruited. Typically, the composite score mNIS17 Ionis and its component scores detected and broadly scaled these abnormalities with sufficient room to recognize expected worsening. From a review of the distribution of the kind and severities of polyneuropathy signs and neurophysiologic test abnormalities, it appeared that the goal of recruiting a broad range of severities of FAP severities is being achieved in this trial. Component scores of mNIS17 Ionis without abnormality at baseline evaluations (mean of 2 evaluations) were: NIS-R (n 5 7), S ST QSTing of HP5 (n 5 22), and several other endpoints (Fig. 1) . None of the recruited patients had mNIS17 Ionis scores at ceiling. However, ceiling scores were observed for some subscores: NIS reflexes (n 5 8), S ST QSTing of HP5 (n 5 1), and HR db (n 5 7). Overall, we judged that mNIS17 Ionis broadly detected and scaled polyneuropathy abnormality over a broad range of different expressions and severities.
Availability of highly standardized neurophysiologic tests, reference values of NC, and quantitative sensation tests in the mNIS17 Ionis composite score allowed us to test for the accuracy of closely matched clinical signs. Most clinical signs had been accurately assessed by international neurologists. This conclusion was supported by the significant correlation of composite scores of clinical signs with neurophysiologic tests. It is direct evidence that neurologists, given special training and certification, had accurately assessed polyneuropathy signs.
From our correlation studies of polyneuropathy signs as compared to neurophysiologic tests, we also observed that correlations were much stronger for some composite scores of NC than for others. Thus, those chosen for m17 Ionis performed much better than those in 17 (the latter chosen for study of diabetic polyneuropathy and emphasizing attributes of NC velocity and distal latencies). We also note that the strong correlations between assessed neuropathy signs and neurophysiologic tests came from assessments made at 16 medical centers located in 6 different countries, providing evidence that mNIS17 Ionis can be assessed accurately and proficiently at multiple medical centers and in different countries. However, we judge that the good clinometric performance of neurologists and neurophysiologists observed here came from performance related to insights gained from previously conducted Clinical versus Neurophysiologic Trials (Cl vs. NPhys), [33] [34] [35] 38, 39 The choice of expert neurologists and clinical neurophysiologists, special training sessions to grade abnormality specifically using appropriate reference values, and quality control at a central reading and quality assurance center probably contributed to the observed accuracy of polyneuropathy measurements.
How broadly applicable is mNIS17 Ionis for therapeutic trials in other countries or other neuropathies? From our results it appears that rigorous trials are possible in multiple countries assuming that the approaches found to be useful in this trial are used. However, whether mNIS17 Ionis would find usefulness in trials of other polyneuropathies cannot be inferred from the results of this trial.
Another question, not directly addressed in this trial, is whether mNIS17 Ionis can be scored or used without the involvement of MC PNRL personnel. We assume that it can, knowing that normative reference values of attributes of NC are widely available and that reference values of quantitative sensation and autonomic tests will increasingly be published or made available to users by neurophysiologic instrument makers.
This study has demonstrated that accurate grading of clinical neuromuscular impairments can be performed to the degree that it correlates with neurophysiologic tests and other health outcomes in FAP. The clinical approaches to accurate grading of polyneuropathy signs was inferred from results of Cl versus NPhys Trials 1 and 2. 34, 35 In Cl versus NPhys trial 1, 34 12 international neuromuscular experts evaluated and recorded the polyneuropathy signs of 24 patients with diabetes and with and without polyneuropathy. The appearances and voices of patients were masked. Each patient was examined on a second occasion. In this trial, the experts markedly over-reported polyneuropathy signs and the diagnosis of polyneuropathy as compared to independently assessed, referenced, and sensitive NC abnormality.
In addition, their judgment of abnormality of polyneuropathy signs and diagnosis of polyneuropathy were excessively variable among themselves. When the same trial was repeated approximately 1 year later, 35 but on this occasion using a consensus process emphasizing more specific use of "unequivocal abnormality" of signs for the diagnosis of polyneuropathy, an improvement in accuracy and proficiency resulted. Therefore, for the conduct of the NEURO-TTR trial of FAP and as discussed in the Materials and Methods section, a series of steps were taken to encourage neurologists to grade abnormality of polyneuropathy signs using specific criteria, comparison to healthy subjects, and to be objective and specific in their assessments. In their judgment of neuropathic abnormality, neurologists were asked not to include signs attributable to old age, previous or concurrent disease, or injury other than FAP. In addition, all of the evaluations underwent surveillance at the central MC PNRL to encourage compliance with these standards.
The availability of m17 Ionis neurophysiologic test results in the mNIS17 Ionis score provided a built-in standard by which the accuracy of clinical signs could be judged. It was reassuring that most clinical signs for which a comparable neurophysiologic test had also been measured were found to be strongly correlated. Furthermore, it was reassuring that severity of polyneuropathy signs or symptoms assessed more broadly also correlated with neurophysiologic tests.
It is an important finding of this study that the entire score NIS (and even mNIS17 Ionis ) performed as well or better than any of its subscores. This fact provides evidence that we have not included subscores that dilute the correlation of the overall scores. We also assessed whether the different symptom or disability scores performed as well or better than NIS or of one of its subscores in correlation with neurophysiologic tests. They did not, with 2 exceptions, i.e., S ST QSTing of HP5 and HR db . Whereas NIS and its subscores did not correlate with somatotopic assessment of HP5 or with HR db , the autonomic subscores of NSC did.
The question of whether small fiber sensory (S ST QSTing of HP) or autonomic (HR db ) dysfunction measures should be included in mNIS17 Ionis needs to be considered, because S ST QSTing of HP5 did not correlate with most other polyneuropathy measures in mNIS17 Ionis . Also, test/retest reproducibility was not as high as it was for some other neuropathy measurements. Nevertheless, we judge that S ST QSTing of HP5 should be included in mNIS17 Ionis , because selective small fiber sensory loss would not be adequately assessed and this abnormality occurs to a marked degree in a subset of FAP patients.
The strong correlations of mNIS17 Ionis or its subscores with disability and health scores was helpful in demonstrating that the entire score provided as strong or stronger correlations with disability or health scores than did their component subscores. However, we observed that some of the component subscores, e.g., NIS, NIS-W, NSC-W, and others, performed very well also.
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